Kerry completed his PhD in Medical Statistics part-time, whilst working as a Statistician in the National Health Service in the UK. Following spells with Ciba-Geigy AG (now Novartis) in Basel, Switzerland and the University of Kent at Canterbury, UK, Kerry joined Quintiles in Bracknell, UK in 1993. He has gained considerable experience in the design, analysis and reporting of pre-clinical as well as Phase I, II, III and IV clinical trials, across a very wide range of therapeutic areas. He has been particularly involved with regulatory submissions in diabetes, migraine, Parkinson’s disease, transplantation and vaccines.

Sara Hughes is SVP & Head, Biostatistics at GSK. Her global group provides statistics, programming and data science resources for the full range of R&D activities in GSK's pharmaceutical and vaccines portfolio. Sara herself sits on GSK's Clinical Development Leadership Team and also the senior R&D technical and investment governance boards, where she and other Biostats leaders champion the use of quantitative decision-making approaches. Externally, Sara is a past-president of PSI, and was a member of the PSI Board of Directors for nine years. Sara has published around 30 papers in peer-reviewed journals.

James joined AstraZeneca in November 2013 as the Head of Early Clinical Development Biometrics. After completing his MSc in Statistics at Imperial College, London, he began his career as a Research Fellow at the Applied Statistics Research Unit at the University of Kent, UK working for 5 years in various applications of statistics but particularly in the area of clinical cross-over trials, linear and non-linear modelling and Bayesian methods. He then completed 21 years at Amgen where he worked on the development and regulatory/ reimbursement approval of many of their biotechnology products, representing the company at regulatory submissions in the US and the EU and eventually chairing the company’s International Protocol Review Committee.